1468 related articles for article (PubMed ID: 33592120)
1. Current treatment and recent progress in gastric cancer.
Joshi SS; Badgwell BD
CA Cancer J Clin; 2021 May; 71(3):264-279. PubMed ID: 33592120
[TBL] [Abstract][Full Text] [Related]
2. Updates on Management of Gastric Cancer.
Johnston FM; Beckman M
Curr Oncol Rep; 2019 Jun; 21(8):67. PubMed ID: 31236716
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
[TBL] [Abstract][Full Text] [Related]
4. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
5. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH
Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987
[TBL] [Abstract][Full Text] [Related]
6. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
[TBL] [Abstract][Full Text] [Related]
7. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma.
Levenson G; Voron T; Paye F; Balladur P; Debove C; Chafai N; De Dios AG; Lefevre JH; Parc Y
Surgery; 2021 Dec; 170(6):1711-1717. PubMed ID: 34561115
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
9. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
Kim JW; Cho SY; Chae J; Kim JW; Kim TY; Lee KW; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2020 Oct; 52(4):1178-1187. PubMed ID: 32599979
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
12. Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab.
Hackshaw MD; Bui CL; Ladner A; Tu N; Islam Z; Ritchey ME; Salas M
Cancer Treat Res Commun; 2020; 24():100189. PubMed ID: 32673845
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
14. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for resectable microsatellite instability-high gastric cancer?
Lordick F
Lancet Oncol; 2020 Feb; 21(2):203. PubMed ID: 32007193
[No Abstract] [Full Text] [Related]
16. Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
Jones JO; Smyth EC
Cancer Treat Rev; 2020 Mar; 84():101950. PubMed ID: 31918022
[TBL] [Abstract][Full Text] [Related]
17. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
18. Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma.
Birla R; Hoara P; Caragui A; Cristian M; Constantinoiu S
Chirurgia (Bucur); 2018; 113(1):38-45. PubMed ID: 29509530
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for gastric cancer: current and future directions.
Foo M; Leong T
World J Gastroenterol; 2014 Oct; 20(38):13718-27. PubMed ID: 25320509
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: what are the current options?
Gronnier C; Piessen G; Mariette C
J Visc Surg; 2012 Feb; 149(1):e23-33. PubMed ID: 22341763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]